SPY336.78+1.21 0.36%
DIA280.96+2.82 1.01%
IXIC10,925.80-42.56 -0.39%

UPDATE: Morgan Stanley Initiates Cabaletta With Overweight, $19 Target Notes Co. Is 'Harnessing The Power Of Cell Therapy For Autoimmune Diseases'; 'CAAR T is a novel cell therapy which could potentially cure a wide variety of autoimmune disorders'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · -